X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES UNICHEM LAB JUBILANT LIFE SCIENCES/
UNICHEM LAB
 
P/E (TTM) x 17.2 -64.6 - View Chart
P/BV x 4.5 0.7 625.6% View Chart
Dividend Yield % 0.4 2.3 17.2%  

Financials

 JUBILANT LIFE SCIENCES   UNICHEM LAB
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
UNICHEM LAB
Mar-18
JUBILANT LIFE SCIENCES/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs187382 48.9%   
Low Rs65234 27.8%   
Sales per share (Unadj.) Rs364.3116.3 313.3%  
Earnings per share (Unadj.) Rs6.8-18.9 -36.2%  
Cash flow per share (Unadj.) Rs24.5-11.7 -208.7%  
Dividends per share (Unadj.) Rs3.005.00 60.0%  
Dividend yield (eoy) %2.41.6 146.7%  
Book value per share (Unadj.) Rs164.9381.0 43.3%  
Shares outstanding (eoy) m159.2870.34 226.4%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.32.6 13.1%   
Avg P/E ratio x18.4-16.3 -113.0%  
P/CF ratio (eoy) x5.1-26.2 -19.6%  
Price / Book Value ratio x0.80.8 94.5%  
Dividend payout %43.8-26.4 -165.8%   
Avg Mkt Cap Rs m20,06121,668 92.6%   
No. of employees `0006.22.3 271.3%   
Total wages/salary Rs m11,0522,006 550.8%   
Avg. sales/employee Rs Th9,383.03,587.8 261.5%   
Avg. wages/employee Rs Th1,786.9880.0 203.1%   
Avg. net profit/employee Rs Th176.3-583.7 -30.2%   
INCOME DATA
Net Sales Rs m58,0348,180 709.4%  
Other income Rs m191610 31.2%   
Total revenues Rs m58,2248,790 662.4%   
Gross profit Rs m5,786-1,320 -438.3%  
Depreciation Rs m2,812505 556.7%   
Interest Rs m3,23780 4,041.4%   
Profit before tax Rs m-72-1,295 5.6%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m69633 2,083.8%   
Profit after tax Rs m1,090-1,331 -81.9%  
Gross profit margin %10.0-16.1 -61.8%  
Effective tax rate %-965.9-2.6 37,435.8%   
Net profit margin %1.9-16.3 -11.5%  
BALANCE SHEET DATA
Current assets Rs m29,28023,318 125.6%   
Current liabilities Rs m38,9124,635 839.5%   
Net working cap to sales %-16.6228.4 -7.3%  
Current ratio x0.85.0 15.0%  
Inventory Days Days84122 69.3%  
Debtors Days Days51121 41.7%  
Net fixed assets Rs m55,7128,163 682.5%   
Share capital Rs m155141 109.8%   
"Free" reserves Rs m20,96826,660 78.6%   
Net worth Rs m26,26526,801 98.0%   
Long term debt Rs m17,1693 520,266.7%   
Total assets Rs m88,60631,890 277.9%  
Interest coverage x1.0-15.2 -6.4%   
Debt to equity ratio x0.70 530,878.0%  
Sales to assets ratio x0.70.3 255.3%   
Return on assets %4.9-3.9 -124.5%  
Return on equity %4.2-5.0 -83.6%  
Return on capital %11.6-4.5 -254.7%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,0044,356 505.1%   
Fx outflow Rs m11,7490-   
Net fx Rs m10,2554,356 235.4%   
CASH FLOW
From Operations Rs m8,026-1,123 -714.4%  
From Investments Rs m-1,74416,487 -10.6%  
From Financial Activity Rs m-4,447-8,811 50.5%  
Net Cashflow Rs m1,8346,552 28.0%  

Share Holding

Indian Promoters % 45.6 50.1 91.0%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 15.1 57.6%  
FIIs % 21.2 3.0 706.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 31.7 66.6%  
Shareholders   23,815 20,176 118.0%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ABBOTT INDIA  NATCO PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1% (Quarterly Result Update)

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 19, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS